Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells ( alization of its productcandidates di...)

Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells

alization of its product candidates, difficulties or delays in its pre-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

CONTACT: Vince Reardon, Sr. Director, Investor Relations, InvestorRelations & Corporate Communications of Anadys Pharmaceuticals, Inc.,+1-858-530-3653, vreardon@anadyspharma.com

Web site: http://www.anadyspharma.com/

Ticker Symbol: (NASDAQ-NMS:ANDS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Page: 1 2 3 4
Related medicine technology :

1. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

Post Your Comments:

(Date:12/1/2008)...ecember 9 at 11:00 am ET to Discuss Phase 2 Study ... Calif., Dec. 1 Sunesi...armaceutical company focused on the development an...today announced new data from its studies of vorel...nted during the 50th American Society of Hematolog...

(Date:11/28/2008)...ire/ -- German biotech company,Partec is expandin...ing and,AIDS patient follow-up diagnostics for de..., 2.5 million patient tests have been performed wi...Flow" system, supporting already,more than 1 mill...on of the,Partec innovation, the average cost of ...

(Date:11/26/2008)...RANKLIN, Mass., Nov. 26 ...nced today that it has received full approval from...ts U.S. pivotal trial to study the effectiveness o...ted therapy in the prevention of Contrast-Induced ...d PLC,s request to expand their investigation from...

(Date:11/25/2008)...swire-FirstCall/ -- Poniard,Pharmaceuticals, Inc....cused on,innovative oncology therapies, announced...atives for its preclinical research programs in or...n the clinical development of picoplatin,its lea...mmercialization of,picoplatin in the treatment of...

[0] Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH [0] German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 [0] PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.[0] Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin

...(OMX Nordic: ACTI) presented,pre-clinical results ...pean League Against Rheumatism, <a target="_blank"...nference, June,13-16*. , "The new pre-clinical dat...itory effect on disease development in an,experime...ed Sven,Andréasson, President & CEO Act...

...search, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire... the results of scientific studies that,(1) demons...eating,multiple types of human tumors in animal mo...rts its effects, and (3) show that,MPC-6827 is not...d,in cancer drug resistance. The study results app...

Other Medicine Technology:New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2 New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2 New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3 New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4 New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5 New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6

New Positive Pre-clinical Data for Active Biotech's RA Project I-3D New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines

(Date:12/2/2008)...RNewswire/ -- MedPro Imaging, a premier provider,...d the appointment of three,new ultrasound sales p...ve,expansion. The company also announced the rel...due to substantial growth throughout 2008. Keith,...nt of Sales and Marketing in,February of this yea...

(Date:12/2/2008)... keep driving safe, research shows , , T... on a cell phone are more distracted and more pron...d sitting next to them in the car, a new report fi...oint attention, so when you have a person sitting ...erson actually understands something about traffic...

(Date:12/2/2008)..., Kessler Foundation continues to improve the live...ST ORANGE, N.J.Dec. 2 One of the l... disabilities, Henry H. Kessler Foundation, announ...oundation. The Foundation is also changing the nam... Research Center and Kessler Foundation Program Ce...

(Date:12/2/2008)...lf Have Skipped Medical Care Due to Cost Issues- ,...swire/ -- A new survey released today by the Natio...hts another troubling aspect of the current financ...care for themselves or their families to save mone...ir health has gotten worse over the past five year...

Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2 Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2 Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3 Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2 Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3 Health News:Rising Health Costs Prompt Women to Neglect Health 2 Health News:Rising Health Costs Prompt Women to Neglect Health 3 Health News:Rising Health Costs Prompt Women to Neglect Health 4

[0] MedPro Imaging Continues Aggressive U.S. Expansion [0] Car Cell Phone Use More Hazardous Than Chat With Passengers [0] Henry H. Kessler Foundation Rebranded as Kessler Foundation [0] Rising Health Costs Prompt Women to Neglect Health

...Carolina at Chapel Hill, in the current issue of P... may be possible molecular origin of at least nine... These neuro degenerative diseases, including Hunt...posit of proteins inside nerve cells. This deposit...

...logged arteries leading to a condition of early at...n the current issue of Psychosomatic Medicine. How...any such tendencies, said the study. The researche...and had found increased thickness of the lining of...

...he journal Antimicrobial Agents and Chemotherapy p...s that occur in the human saliva can lead to new w...y in children. Researchers at the University of Wa...ne a possible correlation between dental caries (t...

...l death for elderly people. A new study conducted ...s are four times more likely to fall than those wh...e are estimated to have type 2 diabetes, and the n... people by 2025. Previous investigations have def...

Other Medicine News:

Cell molecules behind neuro degenerative diseases Stressful Work Can Put Men At Risk Of Having Blocked Arteries Researchers Discover New Clues To Identify Tooth Decay,Diabetics increases likelihood of falling and associated accidental injury in elders

Herpes Simplex Virus 2 IgG ELISA.

Cytomegalovirus IgM ELISA.

Small Incision Microforceps: Tano ILM Forceps

Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling

Medicine Products:

HSV 2 IgG II ELISA CMV IgM II ELISA Small Incision Microforceps: Tano ILM Forceps Microforceps: Hockeystick

( alization of its productcandidates di...)Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells,Health